nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—ABCB1—Mitomycin—urinary bladder cancer	0.131	0.381	CbGbCtD
Maprotiline—HTR7—vas deferens—urinary bladder cancer	0.0406	0.2	CbGeAlD
Maprotiline—ABCB1—Gemcitabine—urinary bladder cancer	0.0377	0.11	CbGbCtD
Maprotiline—CYP1A2—Fluorouracil—urinary bladder cancer	0.0369	0.107	CbGbCtD
Maprotiline—CHRM3—ureter—urinary bladder cancer	0.0327	0.161	CbGeAlD
Maprotiline—CYP1A2—Etoposide—urinary bladder cancer	0.0308	0.0894	CbGbCtD
Maprotiline—ABCB1—Cisplatin—urinary bladder cancer	0.0274	0.0796	CbGbCtD
Maprotiline—ABCB1—Etoposide—urinary bladder cancer	0.0269	0.0782	CbGbCtD
Maprotiline—CHRM3—muscle of abdomen—urinary bladder cancer	0.0235	0.116	CbGeAlD
Maprotiline—ABCB1—Doxorubicin—urinary bladder cancer	0.0183	0.0533	CbGbCtD
Maprotiline—ABCB1—Methotrexate—urinary bladder cancer	0.0178	0.0517	CbGbCtD
Maprotiline—CYP2D6—Doxorubicin—urinary bladder cancer	0.0173	0.0503	CbGbCtD
Maprotiline—CYP1A2—urine—urinary bladder cancer	0.00806	0.0396	CbGeAlD
Maprotiline—HTR2A—urine—urinary bladder cancer	0.0063	0.031	CbGeAlD
Maprotiline—CYP2D6—urine—urinary bladder cancer	0.00574	0.0282	CbGeAlD
Maprotiline—ORM1—prostate gland—urinary bladder cancer	0.00502	0.0247	CbGeAlD
Maprotiline—CHRM5—epithelium—urinary bladder cancer	0.00501	0.0246	CbGeAlD
Maprotiline—CHRM2—prostate gland—urinary bladder cancer	0.00468	0.023	CbGeAlD
Maprotiline—CHRM1—prostate gland—urinary bladder cancer	0.00426	0.0209	CbGeAlD
Maprotiline—CHRM3—prostate gland—urinary bladder cancer	0.00381	0.0187	CbGeAlD
Maprotiline—ORM1—female reproductive system—urinary bladder cancer	0.00274	0.0135	CbGeAlD
Maprotiline—HRH1—prostate gland—urinary bladder cancer	0.00271	0.0133	CbGeAlD
Maprotiline—CHRM3—smooth muscle tissue—urinary bladder cancer	0.0027	0.0133	CbGeAlD
Maprotiline—HTR7—epithelium—urinary bladder cancer	0.00267	0.0131	CbGeAlD
Maprotiline—CHRM3—renal system—urinary bladder cancer	0.0026	0.0128	CbGeAlD
Maprotiline—HTR7—smooth muscle tissue—urinary bladder cancer	0.00257	0.0126	CbGeAlD
Maprotiline—CHRM3—urethra—urinary bladder cancer	0.00255	0.0125	CbGeAlD
Maprotiline—HTR7—renal system—urinary bladder cancer	0.00247	0.0122	CbGeAlD
Maprotiline—HTR2C—female reproductive system—urinary bladder cancer	0.00246	0.0121	CbGeAlD
Maprotiline—CHRM1—female reproductive system—urinary bladder cancer	0.00232	0.0114	CbGeAlD
Maprotiline—CHRM3—female reproductive system—urinary bladder cancer	0.00208	0.0102	CbGeAlD
Maprotiline—SLC6A2—female reproductive system—urinary bladder cancer	0.00205	0.0101	CbGeAlD
Maprotiline—HRH1—epithelium—urinary bladder cancer	0.00199	0.00979	CbGeAlD
Maprotiline—HTR7—female reproductive system—urinary bladder cancer	0.00198	0.00974	CbGeAlD
Maprotiline—CYP1A2—renal system—urinary bladder cancer	0.00197	0.0097	CbGeAlD
Maprotiline—HRH1—smooth muscle tissue—urinary bladder cancer	0.00192	0.00943	CbGeAlD
Maprotiline—HRH1—urethra—urinary bladder cancer	0.00181	0.00892	CbGeAlD
Maprotiline—HTR2A—epithelium—urinary bladder cancer	0.00166	0.00818	CbGeAlD
Maprotiline—ORM1—lymph node—urinary bladder cancer	0.0016	0.00788	CbGeAlD
Maprotiline—HTR2A—smooth muscle tissue—urinary bladder cancer	0.0016	0.00788	CbGeAlD
Maprotiline—HTR2A—renal system—urinary bladder cancer	0.00154	0.00758	CbGeAlD
Maprotiline—ABCB1—prostate gland—urinary bladder cancer	0.00148	0.00729	CbGeAlD
Maprotiline—HRH1—female reproductive system—urinary bladder cancer	0.00148	0.00727	CbGeAlD
Maprotiline—CYP2D6—renal system—urinary bladder cancer	0.0014	0.00691	CbGeAlD
Maprotiline—HRH1—vagina—urinary bladder cancer	0.00134	0.00658	CbGeAlD
Maprotiline—ABCB1—seminal vesicle—urinary bladder cancer	0.00125	0.00617	CbGeAlD
Maprotiline—HTR2A—female reproductive system—urinary bladder cancer	0.00123	0.00607	CbGeAlD
Maprotiline—SLC6A2—lymph node—urinary bladder cancer	0.0012	0.00591	CbGeAlD
Maprotiline—CYP2D6—female reproductive system—urinary bladder cancer	0.00112	0.00553	CbGeAlD
Maprotiline—HTR2A—vagina—urinary bladder cancer	0.00112	0.00549	CbGeAlD
Maprotiline—ABCB1—epithelium—urinary bladder cancer	0.00109	0.00536	CbGeAlD
Maprotiline—ABCB1—renal system—urinary bladder cancer	0.00101	0.00497	CbGeAlD
Maprotiline—ABCB1—urethra—urinary bladder cancer	0.000993	0.00488	CbGeAlD
Maprotiline—HRH1—lymph node—urinary bladder cancer	0.000865	0.00425	CbGeAlD
Maprotiline—ABCB1—female reproductive system—urinary bladder cancer	0.000809	0.00398	CbGeAlD
Maprotiline—ABCB1—vagina—urinary bladder cancer	0.000732	0.0036	CbGeAlD
Maprotiline—Drowsiness—Methotrexate—urinary bladder cancer	0.000474	0.00121	CcSEcCtD
Maprotiline—ABCB1—lymph node—urinary bladder cancer	0.000473	0.00233	CbGeAlD
Maprotiline—Pancytopenia—Epirubicin—urinary bladder cancer	0.000472	0.00121	CcSEcCtD
Maprotiline—Hypotension—Etoposide—urinary bladder cancer	0.000471	0.0012	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00047	0.0012	CcSEcCtD
Maprotiline—Muscular weakness—Doxorubicin—urinary bladder cancer	0.00047	0.0012	CcSEcCtD
Maprotiline—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000467	0.00119	CcSEcCtD
Maprotiline—Dizziness—Thiotepa—urinary bladder cancer	0.000465	0.00119	CcSEcCtD
Maprotiline—Stomatitis—Methotrexate—urinary bladder cancer	0.000462	0.00118	CcSEcCtD
Maprotiline—Urticaria—Fluorouracil—urinary bladder cancer	0.000462	0.00118	CcSEcCtD
Maprotiline—Dysphagia—Doxorubicin—urinary bladder cancer	0.00046	0.00118	CcSEcCtD
Maprotiline—Pollakiuria—Epirubicin—urinary bladder cancer	0.000459	0.00117	CcSEcCtD
Maprotiline—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000459	0.00117	CcSEcCtD
Maprotiline—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000456	0.00116	CcSEcCtD
Maprotiline—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000454	0.00116	CcSEcCtD
Maprotiline—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000454	0.00116	CcSEcCtD
Maprotiline—Paraesthesia—Etoposide—urinary bladder cancer	0.000453	0.00116	CcSEcCtD
Maprotiline—Weight increased—Epirubicin—urinary bladder cancer	0.000453	0.00116	CcSEcCtD
Maprotiline—Weight decreased—Epirubicin—urinary bladder cancer	0.00045	0.00115	CcSEcCtD
Maprotiline—Somnolence—Etoposide—urinary bladder cancer	0.000449	0.00115	CcSEcCtD
Maprotiline—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000448	0.00114	CcSEcCtD
Maprotiline—Vomiting—Thiotepa—urinary bladder cancer	0.000447	0.00114	CcSEcCtD
Maprotiline—Drowsiness—Epirubicin—urinary bladder cancer	0.000443	0.00113	CcSEcCtD
Maprotiline—Infestation—Epirubicin—urinary bladder cancer	0.000443	0.00113	CcSEcCtD
Maprotiline—Infestation NOS—Epirubicin—urinary bladder cancer	0.000443	0.00113	CcSEcCtD
Maprotiline—Rash—Thiotepa—urinary bladder cancer	0.000443	0.00113	CcSEcCtD
Maprotiline—Dermatitis—Thiotepa—urinary bladder cancer	0.000442	0.00113	CcSEcCtD
Maprotiline—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000442	0.00113	CcSEcCtD
Maprotiline—Headache—Thiotepa—urinary bladder cancer	0.00044	0.00112	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00044	0.00112	CcSEcCtD
Maprotiline—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000437	0.00112	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000436	0.00111	CcSEcCtD
Maprotiline—Body temperature increased—Cisplatin—urinary bladder cancer	0.000435	0.00111	CcSEcCtD
Maprotiline—Fatigue—Etoposide—urinary bladder cancer	0.000435	0.00111	CcSEcCtD
Maprotiline—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000435	0.00111	CcSEcCtD
Maprotiline—Stomatitis—Epirubicin—urinary bladder cancer	0.000432	0.0011	CcSEcCtD
Maprotiline—Jaundice—Epirubicin—urinary bladder cancer	0.000432	0.0011	CcSEcCtD
Maprotiline—Constipation—Etoposide—urinary bladder cancer	0.000431	0.0011	CcSEcCtD
Maprotiline—Hepatitis—Methotrexate—urinary bladder cancer	0.000425	0.00109	CcSEcCtD
Maprotiline—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000425	0.00109	CcSEcCtD
Maprotiline—Asthenia—Gemcitabine—urinary bladder cancer	0.000424	0.00108	CcSEcCtD
Maprotiline—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00042	0.00107	CcSEcCtD
Maprotiline—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00042	0.00107	CcSEcCtD
Maprotiline—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000419	0.00107	CcSEcCtD
Maprotiline—Weight increased—Doxorubicin—urinary bladder cancer	0.000419	0.00107	CcSEcCtD
Maprotiline—Pruritus—Gemcitabine—urinary bladder cancer	0.000418	0.00107	CcSEcCtD
Maprotiline—Nausea—Thiotepa—urinary bladder cancer	0.000417	0.00107	CcSEcCtD
Maprotiline—Urethral disorder—Methotrexate—urinary bladder cancer	0.000417	0.00107	CcSEcCtD
Maprotiline—Weight decreased—Doxorubicin—urinary bladder cancer	0.000416	0.00106	CcSEcCtD
Maprotiline—Feeling abnormal—Etoposide—urinary bladder cancer	0.000416	0.00106	CcSEcCtD
Maprotiline—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000414	0.00106	CcSEcCtD
Maprotiline—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000413	0.00105	CcSEcCtD
Maprotiline—Pruritus—Fluorouracil—urinary bladder cancer	0.000411	0.00105	CcSEcCtD
Maprotiline—Drowsiness—Doxorubicin—urinary bladder cancer	0.00041	0.00105	CcSEcCtD
Maprotiline—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00041	0.00105	CcSEcCtD
Maprotiline—Infestation—Doxorubicin—urinary bladder cancer	0.00041	0.00105	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000407	0.00104	CcSEcCtD
Maprotiline—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000404	0.00103	CcSEcCtD
Maprotiline—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000402	0.00103	CcSEcCtD
Maprotiline—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000402	0.00103	CcSEcCtD
Maprotiline—Urticaria—Etoposide—urinary bladder cancer	0.000401	0.00102	CcSEcCtD
Maprotiline—Jaundice—Doxorubicin—urinary bladder cancer	0.0004	0.00102	CcSEcCtD
Maprotiline—Stomatitis—Doxorubicin—urinary bladder cancer	0.0004	0.00102	CcSEcCtD
Maprotiline—Abdominal pain—Etoposide—urinary bladder cancer	0.000399	0.00102	CcSEcCtD
Maprotiline—Body temperature increased—Etoposide—urinary bladder cancer	0.000399	0.00102	CcSEcCtD
Maprotiline—Hepatitis—Epirubicin—urinary bladder cancer	0.000398	0.00102	CcSEcCtD
Maprotiline—Eye disorder—Methotrexate—urinary bladder cancer	0.000398	0.00102	CcSEcCtD
Maprotiline—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000398	0.00102	CcSEcCtD
Maprotiline—Tinnitus—Methotrexate—urinary bladder cancer	0.000397	0.00101	CcSEcCtD
Maprotiline—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000396	0.00101	CcSEcCtD
Maprotiline—Asthenia—Cisplatin—urinary bladder cancer	0.000395	0.00101	CcSEcCtD
Maprotiline—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000395	0.00101	CcSEcCtD
Maprotiline—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000393	0.001	CcSEcCtD
Maprotiline—Urethral disorder—Epirubicin—urinary bladder cancer	0.00039	0.000997	CcSEcCtD
Maprotiline—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000388	0.000991	CcSEcCtD
Maprotiline—Angiopathy—Methotrexate—urinary bladder cancer	0.000386	0.000986	CcSEcCtD
Maprotiline—Dizziness—Fluorouracil—urinary bladder cancer	0.000384	0.000981	CcSEcCtD
Maprotiline—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000383	0.000979	CcSEcCtD
Maprotiline—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000383	0.000978	CcSEcCtD
Maprotiline—Diarrhoea—Cisplatin—urinary bladder cancer	0.000377	0.000962	CcSEcCtD
Maprotiline—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000376	0.000961	CcSEcCtD
Maprotiline—Alopecia—Methotrexate—urinary bladder cancer	0.000376	0.00096	CcSEcCtD
Maprotiline—Vomiting—Gemcitabine—urinary bladder cancer	0.000376	0.00096	CcSEcCtD
Maprotiline—Rash—Gemcitabine—urinary bladder cancer	0.000373	0.000952	CcSEcCtD
Maprotiline—Dermatitis—Gemcitabine—urinary bladder cancer	0.000372	0.000951	CcSEcCtD
Maprotiline—Eye disorder—Epirubicin—urinary bladder cancer	0.000372	0.00095	CcSEcCtD
Maprotiline—Tinnitus—Epirubicin—urinary bladder cancer	0.000371	0.000948	CcSEcCtD
Maprotiline—Malnutrition—Methotrexate—urinary bladder cancer	0.00037	0.000946	CcSEcCtD
Maprotiline—Headache—Gemcitabine—urinary bladder cancer	0.00037	0.000945	CcSEcCtD
Maprotiline—Flushing—Epirubicin—urinary bladder cancer	0.000369	0.000944	CcSEcCtD
Maprotiline—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000369	0.000944	CcSEcCtD
Maprotiline—Vomiting—Fluorouracil—urinary bladder cancer	0.000369	0.000943	CcSEcCtD
Maprotiline—Hepatitis—Doxorubicin—urinary bladder cancer	0.000368	0.000941	CcSEcCtD
Maprotiline—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000367	0.000936	CcSEcCtD
Maprotiline—Rash—Fluorouracil—urinary bladder cancer	0.000366	0.000936	CcSEcCtD
Maprotiline—Dermatitis—Fluorouracil—urinary bladder cancer	0.000366	0.000935	CcSEcCtD
Maprotiline—Headache—Fluorouracil—urinary bladder cancer	0.000364	0.00093	CcSEcCtD
Maprotiline—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000364	0.000929	CcSEcCtD
Maprotiline—Dysgeusia—Methotrexate—urinary bladder cancer	0.000363	0.000926	CcSEcCtD
Maprotiline—Asthenia—Etoposide—urinary bladder cancer	0.000362	0.000925	CcSEcCtD
Maprotiline—Angiopathy—Epirubicin—urinary bladder cancer	0.000361	0.000923	CcSEcCtD
Maprotiline—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000361	0.000922	CcSEcCtD
Maprotiline—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000359	0.000916	CcSEcCtD
Maprotiline—Pruritus—Etoposide—urinary bladder cancer	0.000357	0.000912	CcSEcCtD
Maprotiline—Arrhythmia—Epirubicin—urinary bladder cancer	0.000356	0.000908	CcSEcCtD
Maprotiline—Alopecia—Epirubicin—urinary bladder cancer	0.000352	0.000898	CcSEcCtD
Maprotiline—Nausea—Gemcitabine—urinary bladder cancer	0.000351	0.000896	CcSEcCtD
Maprotiline—Vomiting—Cisplatin—urinary bladder cancer	0.00035	0.000894	CcSEcCtD
Maprotiline—Vision blurred—Methotrexate—urinary bladder cancer	0.000349	0.000891	CcSEcCtD
Maprotiline—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000348	0.00089	CcSEcCtD
Maprotiline—Rash—Cisplatin—urinary bladder cancer	0.000347	0.000887	CcSEcCtD
Maprotiline—Dermatitis—Cisplatin—urinary bladder cancer	0.000347	0.000886	CcSEcCtD
Maprotiline—Malnutrition—Epirubicin—urinary bladder cancer	0.000347	0.000885	CcSEcCtD
Maprotiline—Diarrhoea—Etoposide—urinary bladder cancer	0.000345	0.000882	CcSEcCtD
Maprotiline—Nausea—Fluorouracil—urinary bladder cancer	0.000345	0.000881	CcSEcCtD
Maprotiline—Eye disorder—Doxorubicin—urinary bladder cancer	0.000344	0.000879	CcSEcCtD
Maprotiline—Tinnitus—Doxorubicin—urinary bladder cancer	0.000343	0.000877	CcSEcCtD
Maprotiline—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000342	0.000873	CcSEcCtD
Maprotiline—Flushing—Doxorubicin—urinary bladder cancer	0.000342	0.000873	CcSEcCtD
Maprotiline—Tension—Epirubicin—urinary bladder cancer	0.00034	0.000869	CcSEcCtD
Maprotiline—Dysgeusia—Epirubicin—urinary bladder cancer	0.000339	0.000867	CcSEcCtD
Maprotiline—Nervousness—Epirubicin—urinary bladder cancer	0.000337	0.00086	CcSEcCtD
Maprotiline—Angiopathy—Doxorubicin—urinary bladder cancer	0.000334	0.000854	CcSEcCtD
Maprotiline—Dizziness—Etoposide—urinary bladder cancer	0.000334	0.000852	CcSEcCtD
Maprotiline—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000332	0.000848	CcSEcCtD
Maprotiline—Leukopenia—Methotrexate—urinary bladder cancer	0.000331	0.000847	CcSEcCtD
Maprotiline—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000329	0.00084	CcSEcCtD
Maprotiline—Nausea—Cisplatin—urinary bladder cancer	0.000327	0.000836	CcSEcCtD
Maprotiline—Vision blurred—Epirubicin—urinary bladder cancer	0.000327	0.000834	CcSEcCtD
Maprotiline—Alopecia—Doxorubicin—urinary bladder cancer	0.000326	0.000831	CcSEcCtD
Maprotiline—Convulsion—Methotrexate—urinary bladder cancer	0.000321	0.000819	CcSEcCtD
Maprotiline—Vomiting—Etoposide—urinary bladder cancer	0.000321	0.000819	CcSEcCtD
Maprotiline—Malnutrition—Doxorubicin—urinary bladder cancer	0.000321	0.000819	CcSEcCtD
Maprotiline—Agitation—Epirubicin—urinary bladder cancer	0.000318	0.000813	CcSEcCtD
Maprotiline—Rash—Etoposide—urinary bladder cancer	0.000318	0.000813	CcSEcCtD
Maprotiline—Dermatitis—Etoposide—urinary bladder cancer	0.000318	0.000812	CcSEcCtD
Maprotiline—Headache—Etoposide—urinary bladder cancer	0.000316	0.000807	CcSEcCtD
Maprotiline—Tension—Doxorubicin—urinary bladder cancer	0.000315	0.000804	CcSEcCtD
Maprotiline—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000314	0.000802	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000313	0.0008	CcSEcCtD
Maprotiline—Nervousness—Doxorubicin—urinary bladder cancer	0.000311	0.000795	CcSEcCtD
Maprotiline—Syncope—Epirubicin—urinary bladder cancer	0.000311	0.000794	CcSEcCtD
Maprotiline—Leukopenia—Epirubicin—urinary bladder cancer	0.00031	0.000792	CcSEcCtD
Maprotiline—Palpitations—Epirubicin—urinary bladder cancer	0.000306	0.000782	CcSEcCtD
Maprotiline—Confusional state—Methotrexate—urinary bladder cancer	0.000305	0.000778	CcSEcCtD
Maprotiline—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000305	0.000778	CcSEcCtD
Maprotiline—Vision blurred—Doxorubicin—urinary bladder cancer	0.000302	0.000772	CcSEcCtD
Maprotiline—Convulsion—Epirubicin—urinary bladder cancer	0.0003	0.000767	CcSEcCtD
Maprotiline—Infection—Methotrexate—urinary bladder cancer	0.0003	0.000767	CcSEcCtD
Maprotiline—Nausea—Etoposide—urinary bladder cancer	0.0003	0.000765	CcSEcCtD
Maprotiline—Hypertension—Epirubicin—urinary bladder cancer	0.000299	0.000764	CcSEcCtD
Maprotiline—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000296	0.000757	CcSEcCtD
Maprotiline—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000296	0.000756	CcSEcCtD
Maprotiline—Agitation—Doxorubicin—urinary bladder cancer	0.000295	0.000753	CcSEcCtD
Maprotiline—Anxiety—Epirubicin—urinary bladder cancer	0.000294	0.000751	CcSEcCtD
Maprotiline—Skin disorder—Methotrexate—urinary bladder cancer	0.000294	0.00075	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000293	0.000748	CcSEcCtD
Maprotiline—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000292	0.000746	CcSEcCtD
Maprotiline—Dry mouth—Epirubicin—urinary bladder cancer	0.000289	0.000737	CcSEcCtD
Maprotiline—Syncope—Doxorubicin—urinary bladder cancer	0.000288	0.000734	CcSEcCtD
Maprotiline—Leukopenia—Doxorubicin—urinary bladder cancer	0.000287	0.000733	CcSEcCtD
Maprotiline—Confusional state—Epirubicin—urinary bladder cancer	0.000285	0.000728	CcSEcCtD
Maprotiline—Palpitations—Doxorubicin—urinary bladder cancer	0.000283	0.000724	CcSEcCtD
Maprotiline—Oedema—Epirubicin—urinary bladder cancer	0.000283	0.000722	CcSEcCtD
Maprotiline—Hypotension—Methotrexate—urinary bladder cancer	0.000282	0.000721	CcSEcCtD
Maprotiline—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000282	0.00072	CcSEcCtD
Maprotiline—Infection—Epirubicin—urinary bladder cancer	0.000281	0.000718	CcSEcCtD
Maprotiline—Shock—Epirubicin—urinary bladder cancer	0.000278	0.000711	CcSEcCtD
Maprotiline—Convulsion—Doxorubicin—urinary bladder cancer	0.000278	0.00071	CcSEcCtD
Maprotiline—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000277	0.000708	CcSEcCtD
Maprotiline—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000277	0.000707	CcSEcCtD
Maprotiline—Hypertension—Doxorubicin—urinary bladder cancer	0.000277	0.000707	CcSEcCtD
Maprotiline—Tachycardia—Epirubicin—urinary bladder cancer	0.000276	0.000705	CcSEcCtD
Maprotiline—Skin disorder—Epirubicin—urinary bladder cancer	0.000275	0.000702	CcSEcCtD
Maprotiline—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000273	0.000698	CcSEcCtD
Maprotiline—Insomnia—Methotrexate—urinary bladder cancer	0.000273	0.000698	CcSEcCtD
Maprotiline—Anxiety—Doxorubicin—urinary bladder cancer	0.000272	0.000695	CcSEcCtD
Maprotiline—Paraesthesia—Methotrexate—urinary bladder cancer	0.000271	0.000693	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000271	0.000692	CcSEcCtD
Maprotiline—Somnolence—Methotrexate—urinary bladder cancer	0.000269	0.000686	CcSEcCtD
Maprotiline—Dry mouth—Doxorubicin—urinary bladder cancer	0.000267	0.000682	CcSEcCtD
Maprotiline—Dyspepsia—Methotrexate—urinary bladder cancer	0.000266	0.000679	CcSEcCtD
Maprotiline—Hypotension—Epirubicin—urinary bladder cancer	0.000264	0.000675	CcSEcCtD
Maprotiline—Confusional state—Doxorubicin—urinary bladder cancer	0.000264	0.000674	CcSEcCtD
Maprotiline—Oedema—Doxorubicin—urinary bladder cancer	0.000262	0.000668	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000261	0.000666	CcSEcCtD
Maprotiline—Fatigue—Methotrexate—urinary bladder cancer	0.000261	0.000666	CcSEcCtD
Maprotiline—Infection—Doxorubicin—urinary bladder cancer	0.00026	0.000664	CcSEcCtD
Maprotiline—Shock—Doxorubicin—urinary bladder cancer	0.000257	0.000658	CcSEcCtD
Maprotiline—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000257	0.000655	CcSEcCtD
Maprotiline—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000256	0.000654	CcSEcCtD
Maprotiline—Insomnia—Epirubicin—urinary bladder cancer	0.000256	0.000653	CcSEcCtD
Maprotiline—Tachycardia—Doxorubicin—urinary bladder cancer	0.000255	0.000652	CcSEcCtD
Maprotiline—Skin disorder—Doxorubicin—urinary bladder cancer	0.000254	0.000649	CcSEcCtD
Maprotiline—Paraesthesia—Epirubicin—urinary bladder cancer	0.000254	0.000649	CcSEcCtD
Maprotiline—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000253	0.000646	CcSEcCtD
Maprotiline—Somnolence—Epirubicin—urinary bladder cancer	0.000251	0.000642	CcSEcCtD
Maprotiline—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000249	0.000636	CcSEcCtD
Maprotiline—Dyspepsia—Epirubicin—urinary bladder cancer	0.000249	0.000636	CcSEcCtD
Maprotiline—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000247	0.000631	CcSEcCtD
Maprotiline—Hypotension—Doxorubicin—urinary bladder cancer	0.000245	0.000625	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000244	0.000624	CcSEcCtD
Maprotiline—Fatigue—Epirubicin—urinary bladder cancer	0.000244	0.000623	CcSEcCtD
Maprotiline—Constipation—Epirubicin—urinary bladder cancer	0.000242	0.000618	CcSEcCtD
Maprotiline—Urticaria—Methotrexate—urinary bladder cancer	0.00024	0.000613	CcSEcCtD
Maprotiline—Abdominal pain—Methotrexate—urinary bladder cancer	0.000239	0.00061	CcSEcCtD
Maprotiline—Body temperature increased—Methotrexate—urinary bladder cancer	0.000239	0.00061	CcSEcCtD
Maprotiline—Insomnia—Doxorubicin—urinary bladder cancer	0.000237	0.000605	CcSEcCtD
Maprotiline—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000235	0.0006	CcSEcCtD
Maprotiline—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000233	0.000595	CcSEcCtD
Maprotiline—Somnolence—Doxorubicin—urinary bladder cancer	0.000233	0.000594	CcSEcCtD
Maprotiline—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000231	0.000591	CcSEcCtD
Maprotiline—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00023	0.000588	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000226	0.000577	CcSEcCtD
Maprotiline—Fatigue—Doxorubicin—urinary bladder cancer	0.000226	0.000576	CcSEcCtD
Maprotiline—Urticaria—Epirubicin—urinary bladder cancer	0.000225	0.000574	CcSEcCtD
Maprotiline—Constipation—Doxorubicin—urinary bladder cancer	0.000224	0.000572	CcSEcCtD
Maprotiline—Abdominal pain—Epirubicin—urinary bladder cancer	0.000224	0.000571	CcSEcCtD
Maprotiline—Body temperature increased—Epirubicin—urinary bladder cancer	0.000224	0.000571	CcSEcCtD
Maprotiline—Asthenia—Methotrexate—urinary bladder cancer	0.000217	0.000554	CcSEcCtD
Maprotiline—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000216	0.000551	CcSEcCtD
Maprotiline—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000214	0.000547	CcSEcCtD
Maprotiline—Pruritus—Methotrexate—urinary bladder cancer	0.000214	0.000546	CcSEcCtD
Maprotiline—Urticaria—Doxorubicin—urinary bladder cancer	0.000208	0.000531	CcSEcCtD
Maprotiline—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000207	0.000528	CcSEcCtD
Maprotiline—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000207	0.000528	CcSEcCtD
Maprotiline—Diarrhoea—Methotrexate—urinary bladder cancer	0.000207	0.000528	CcSEcCtD
Maprotiline—Asthenia—Epirubicin—urinary bladder cancer	0.000203	0.000518	CcSEcCtD
Maprotiline—Pruritus—Epirubicin—urinary bladder cancer	0.0002	0.000511	CcSEcCtD
Maprotiline—Dizziness—Methotrexate—urinary bladder cancer	0.0002	0.00051	CcSEcCtD
Maprotiline—Diarrhoea—Epirubicin—urinary bladder cancer	0.000194	0.000494	CcSEcCtD
Maprotiline—Vomiting—Methotrexate—urinary bladder cancer	0.000192	0.000491	CcSEcCtD
Maprotiline—Rash—Methotrexate—urinary bladder cancer	0.000191	0.000487	CcSEcCtD
Maprotiline—Dermatitis—Methotrexate—urinary bladder cancer	0.00019	0.000486	CcSEcCtD
Maprotiline—Headache—Methotrexate—urinary bladder cancer	0.000189	0.000484	CcSEcCtD
Maprotiline—Asthenia—Doxorubicin—urinary bladder cancer	0.000188	0.00048	CcSEcCtD
Maprotiline—Dizziness—Epirubicin—urinary bladder cancer	0.000187	0.000478	CcSEcCtD
Maprotiline—Pruritus—Doxorubicin—urinary bladder cancer	0.000185	0.000473	CcSEcCtD
Maprotiline—Vomiting—Epirubicin—urinary bladder cancer	0.00018	0.000459	CcSEcCtD
Maprotiline—Nausea—Methotrexate—urinary bladder cancer	0.00018	0.000459	CcSEcCtD
Maprotiline—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000179	0.000457	CcSEcCtD
Maprotiline—Rash—Epirubicin—urinary bladder cancer	0.000178	0.000455	CcSEcCtD
Maprotiline—Dermatitis—Epirubicin—urinary bladder cancer	0.000178	0.000455	CcSEcCtD
Maprotiline—Headache—Epirubicin—urinary bladder cancer	0.000177	0.000453	CcSEcCtD
Maprotiline—Dizziness—Doxorubicin—urinary bladder cancer	0.000173	0.000442	CcSEcCtD
Maprotiline—Nausea—Epirubicin—urinary bladder cancer	0.000168	0.000429	CcSEcCtD
Maprotiline—Vomiting—Doxorubicin—urinary bladder cancer	0.000166	0.000425	CcSEcCtD
Maprotiline—Rash—Doxorubicin—urinary bladder cancer	0.000165	0.000421	CcSEcCtD
Maprotiline—Dermatitis—Doxorubicin—urinary bladder cancer	0.000165	0.000421	CcSEcCtD
Maprotiline—Headache—Doxorubicin—urinary bladder cancer	0.000164	0.000419	CcSEcCtD
Maprotiline—Nausea—Doxorubicin—urinary bladder cancer	0.000155	0.000397	CcSEcCtD
Maprotiline—HTR2A—Signaling Pathways—TERT—urinary bladder cancer	1.35e-05	0.000221	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—RHOA—urinary bladder cancer	1.35e-05	0.00022	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.35e-05	0.00022	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TERT—urinary bladder cancer	1.35e-05	0.00022	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL2—urinary bladder cancer	1.34e-05	0.00022	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TERT—urinary bladder cancer	1.34e-05	0.00022	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TERT—urinary bladder cancer	1.34e-05	0.000219	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL2—urinary bladder cancer	1.33e-05	0.000218	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TERT—urinary bladder cancer	1.33e-05	0.000217	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CXCL8—urinary bladder cancer	1.31e-05	0.000214	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—ERBB2—urinary bladder cancer	1.3e-05	0.000213	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PPARG—urinary bladder cancer	1.3e-05	0.000213	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—HRAS—urinary bladder cancer	1.3e-05	0.000213	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	1.26e-05	0.000206	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.25e-05	0.000205	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—CREBBP—urinary bladder cancer	1.25e-05	0.000204	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IL2—urinary bladder cancer	1.25e-05	0.000204	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—ERBB2—urinary bladder cancer	1.25e-05	0.000204	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—FGFR3—urinary bladder cancer	1.24e-05	0.000203	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	1.24e-05	0.000202	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CXCL8—urinary bladder cancer	1.24e-05	0.000202	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.23e-05	0.000201	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—FGFR3—urinary bladder cancer	1.23e-05	0.000201	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—HRAS—urinary bladder cancer	1.23e-05	0.000201	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	1.22e-05	0.0002	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CCND1—urinary bladder cancer	1.22e-05	0.000199	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—FGFR3—urinary bladder cancer	1.22e-05	0.000199	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	1.21e-05	0.000199	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—ESR1—urinary bladder cancer	1.2e-05	0.000197	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	1.2e-05	0.000196	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.2e-05	0.000196	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	1.2e-05	0.000196	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—ESR1—urinary bladder cancer	1.2e-05	0.000196	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	1.19e-05	0.000195	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—ESR1—urinary bladder cancer	1.19e-05	0.000195	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MMP9—urinary bladder cancer	1.18e-05	0.000193	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CXCL8—urinary bladder cancer	1.18e-05	0.000193	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.18e-05	0.000193	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—ESR1—urinary bladder cancer	1.18e-05	0.000193	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL2—urinary bladder cancer	1.18e-05	0.000193	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—CDKN1A—urinary bladder cancer	1.18e-05	0.000193	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PTEN—urinary bladder cancer	1.18e-05	0.000192	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—HRAS—urinary bladder cancer	1.18e-05	0.000192	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.17e-05	0.000191	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.17e-05	0.00019	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	0.000188	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	0.000188	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CCND1—urinary bladder cancer	1.15e-05	0.000188	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL2—urinary bladder cancer	1.13e-05	0.000185	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.13e-05	0.000184	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—EP300—urinary bladder cancer	1.12e-05	0.000183	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MMP9—urinary bladder cancer	1.12e-05	0.000183	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—CDKN1A—urinary bladder cancer	1.11e-05	0.000182	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PTEN—urinary bladder cancer	1.11e-05	0.000182	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.1e-05	0.00018	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CCND1—urinary bladder cancer	1.1e-05	0.00018	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.1e-05	0.00018	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.1e-05	0.00018	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—SRC—urinary bladder cancer	1.09e-05	0.000178	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.09e-05	0.000178	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.09e-05	0.000178	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	0.000177	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	1.07e-05	0.000175	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MMP9—urinary bladder cancer	1.07e-05	0.000175	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CDKN1A—urinary bladder cancer	1.07e-05	0.000174	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PTEN—urinary bladder cancer	1.06e-05	0.000174	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EP300—urinary bladder cancer	1.06e-05	0.000173	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	1.06e-05	0.000173	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.05e-05	0.000172	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	1.05e-05	0.000172	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.05e-05	0.000172	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CREBBP—urinary bladder cancer	1.05e-05	0.000172	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CREBBP—urinary bladder cancer	1.05e-05	0.000171	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	1.04e-05	0.00017	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.04e-05	0.00017	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.04e-05	0.00017	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.04e-05	0.000169	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IGF1—urinary bladder cancer	1.04e-05	0.000169	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CREBBP—urinary bladder cancer	1.04e-05	0.000169	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.03e-05	0.000169	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IGF1—urinary bladder cancer	1.03e-05	0.000169	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—EGFR—urinary bladder cancer	1.03e-05	0.000169	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—SRC—urinary bladder cancer	1.03e-05	0.000168	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—EGFR—urinary bladder cancer	1.03e-05	0.000168	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTGS2—urinary bladder cancer	1.02e-05	0.000167	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IGF1—urinary bladder cancer	1.02e-05	0.000167	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.02e-05	0.000167	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.02e-05	0.000167	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—EGFR—urinary bladder cancer	1.02e-05	0.000166	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.02e-05	0.000166	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.02e-05	0.000166	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EP300—urinary bladder cancer	1.01e-05	0.000166	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1e-05	0.000164	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	9.95e-06	0.000163	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—SRC—urinary bladder cancer	9.87e-06	0.000161	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	9.79e-06	0.00016	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MYC—urinary bladder cancer	9.78e-06	0.00016	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	9.77e-06	0.00016	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	9.74e-06	0.000159	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—KRAS—urinary bladder cancer	9.71e-06	0.000159	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	9.7e-06	0.000159	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.69e-06	0.000158	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	9.65e-06	0.000158	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	9.62e-06	0.000157	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	9.6e-06	0.000157	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	9.59e-06	0.000157	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—EGFR—urinary bladder cancer	9.57e-06	0.000156	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	9.54e-06	0.000156	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	9.52e-06	0.000156	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	9.49e-06	0.000155	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—RHOA—urinary bladder cancer	9.46e-06	0.000155	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	9.37e-06	0.000153	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—TYMS—urinary bladder cancer	9.31e-06	0.000152	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MYC—urinary bladder cancer	9.24e-06	0.000151	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	9.22e-06	0.000151	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	9.2e-06	0.00015	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	9.2e-06	0.00015	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	9.04e-06	0.000148	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	9.03e-06	0.000148	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	8.99e-06	0.000147	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	8.98e-06	0.000147	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTEN—urinary bladder cancer	8.93e-06	0.000146	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	8.84e-06	0.000145	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	8.83e-06	0.000144	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	8.82e-06	0.000144	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GPX1—urinary bladder cancer	8.81e-06	0.000144	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	8.79e-06	0.000144	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	8.76e-06	0.000143	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	8.73e-06	0.000143	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	8.7e-06	0.000142	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	8.68e-06	0.000142	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	8.67e-06	0.000142	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	8.65e-06	0.000141	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	8.65e-06	0.000141	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	8.53e-06	0.000139	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—EP300—urinary bladder cancer	8.52e-06	0.000139	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	8.51e-06	0.000139	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	8.46e-06	0.000138	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	8.38e-06	0.000137	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	8.36e-06	0.000137	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	8.33e-06	0.000136	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	8.32e-06	0.000136	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	8.31e-06	0.000136	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	8.31e-06	0.000136	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	8.28e-06	0.000135	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	8.27e-06	0.000135	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.26e-06	0.000135	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	8.25e-06	0.000135	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	8.23e-06	0.000134	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	8.17e-06	0.000134	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	8.17e-06	0.000134	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL2—urinary bladder cancer	8.14e-06	0.000133	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	8.13e-06	0.000133	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	8.05e-06	0.000132	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—urinary bladder cancer	8.03e-06	0.000131	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	8.01e-06	0.000131	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL2—urinary bladder cancer	7.99e-06	0.000131	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	7.96e-06	0.00013	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	7.94e-06	0.00013	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.94e-06	0.00013	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	7.93e-06	0.00013	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	7.86e-06	0.000129	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	7.81e-06	0.000128	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	7.79e-06	0.000127	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARG—urinary bladder cancer	7.79e-06	0.000127	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	7.76e-06	0.000127	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	7.74e-06	0.000126	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	7.7e-06	0.000126	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	7.68e-06	0.000126	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	7.67e-06	0.000125	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	7.66e-06	0.000125	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	7.66e-06	0.000125	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	7.58e-06	0.000124	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	7.58e-06	0.000124	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	7.56e-06	0.000124	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	7.55e-06	0.000123	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	7.54e-06	0.000123	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.53e-06	0.000123	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	7.53e-06	0.000123	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	7.52e-06	0.000123	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	7.51e-06	0.000123	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.51e-06	0.000123	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	7.49e-06	0.000122	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	7.49e-06	0.000122	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	7.48e-06	0.000122	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	7.47e-06	0.000122	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	7.44e-06	0.000122	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	7.41e-06	0.000121	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	7.4e-06	0.000121	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EP300—urinary bladder cancer	7.3e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	7.26e-06	0.000119	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	7.25e-06	0.000119	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	7.21e-06	0.000118	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	7.18e-06	0.000117	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EP300—urinary bladder cancer	7.17e-06	0.000117	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	7.15e-06	0.000117	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	7.12e-06	0.000116	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SRC—urinary bladder cancer	7.1e-06	0.000116	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	7.05e-06	0.000115	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	7.05e-06	0.000115	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	6.99e-06	0.000114	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SRC—urinary bladder cancer	6.97e-06	0.000114	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	6.95e-06	0.000114	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	6.95e-06	0.000114	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	6.93e-06	0.000113	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	6.86e-06	0.000112	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	6.66e-06	0.000109	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARG—urinary bladder cancer	6.6e-06	0.000108	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.5e-06	0.000106	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MYC—urinary bladder cancer	6.36e-06	0.000104	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	6.34e-06	0.000104	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	6.26e-06	0.000102	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MYC—urinary bladder cancer	6.25e-06	0.000102	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	6.23e-06	0.000102	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	6.22e-06	0.000102	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	6.21e-06	0.000101	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	6.15e-06	0.0001	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	6.12e-06	0.0001	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	6.12e-06	0.0001	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	6.11e-06	9.99e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	6.09e-06	9.96e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	6.07e-06	9.92e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	6.01e-06	9.83e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	5.92e-06	9.68e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	5.88e-06	9.61e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	5.78e-06	9.46e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	5.77e-06	9.44e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	5.75e-06	9.41e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	5.74e-06	9.38e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	5.68e-06	9.28e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.67e-06	9.26e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	5.66e-06	9.26e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—EP300—urinary bladder cancer	5.41e-06	8.84e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.34e-06	8.73e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—urinary bladder cancer	5.23e-06	8.54e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	5.19e-06	8.48e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	5.14e-06	8.4e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—urinary bladder cancer	5.13e-06	8.39e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	5.11e-06	8.36e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	5.1e-06	8.33e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.09e-06	8.33e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	5.05e-06	8.25e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	5e-06	8.17e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	4.92e-06	8.04e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	4.91e-06	8.02e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	4.89e-06	7.99e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	4.88e-06	7.97e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	4.83e-06	7.89e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.52e-06	7.4e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—EP300—urinary bladder cancer	4.32e-06	7.05e-05	CbGpPWpGaD
